Company / Total Debt
Gilead Sciences Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$24.9B
FY2025
5-year range
$24.9B / $26.7B
FY2021-FY2025
Trend
-6.6%
vs FY2024
Sector context
#9 of 83
Health Care
What the data says
Gilead Sciences's total debt of $24.9B is higher than 89% of companies in the Health Care sector (FY2025). Total Debt has fluctuated over the past 10 years, ranging from $22.1B in FY2019 to $31.4B in FY2020.
Based on SEC 10-K filings.
$24.9B in FY2025 with a 5-year CAGR of -4.5%. Top quartile in the Health Care sector.
Remained stable around $24.9B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -0.4%
- 5-Year CAGR
- -4.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 83This company $24.9B Sector average $6.2B
▼
+305.4% above sector average
Key checks
Key Insights
- 5-year CAGR of -4.5%, indicating a declining trend.
- In FY2025, total debt decreased 6.6% year-over-year.
- Ranks #9 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2020.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $24.9B | -6.6% |
| FY2024 | $26.7B | +6.9% |
| FY2023 | $25.0B | -1.0% |
| FY2022 | $25.2B | -5.5% |
| FY2021 | $26.7B | -15.0% |
| FY2020 | $31.4B | +42.1% |
| FY2019 | $22.1B | -10.1% |
| FY2018 | $24.6B | -20.2% |
| FY2017 | $30.8B | +16.9% |
| FY2016 | $26.3B | +18.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026